Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23075263 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23067775 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23067773 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23067788 | 0.94 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL29842524 | 0.94 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23075269 | 0.94 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23067786 | 0.94 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23067751 | 0.93 | RIPK1 (0.89) | RIPK1 | |
| SCHEMBL23075391 | 0.93 | RIPK1 (0.89) | RIPK1 | |
| SCHEMBL23067749 | 0.93 | RIPK1 (0.89) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4025572-B1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4304713-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117083270-A | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2023-11-17 | — | — | CN | claimed |
| WO-2022192533-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| CN-114761398-A | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2022-07-15 | — | — | CN | claimed |
| EP-4025572-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| CN-114761398-B | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4304713-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117083270-A | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022192533-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-114761398-A | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-4025572-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |